HCPCS M-Codes
Medical services

  • M1400

    Patients who died during the follow-up period

  • M1401

    Stages i-iii breast cancer

  • M1402

    Patients receiving an initial chemotherapy regimen with a defined duration with the eligible clinician or group

  • M1403

    Patients with baseline and follow-up promis surveys documented in the medical record

  • M1404

    Patients on a therapeutic clinical trial

  • M1405

    Patients with recurrence/disease progression

  • M1406

    Patients who leave the practice during the follow-up period

  • M1407

    Patients who died during the follow-up period

  • M1408

    Patients who have germline brca testing completed before diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal cancer

  • M1409

    Patients who received germline testing for brca1 and brca2 or genetic counseling completed within 6 months of diagnosis
  • Continued

  • M1410

    Patients who did not have germline testing for brca1 and brca2 or genetic counseling completed within 6 months of diagnosis

  • M1411

    Currently on first-line immune checkpoint inhibitors without chemotherapy

  • M1412

    Patients with metastatic nsclc with epidermal growth factor receptor (egfr) mutations, alk genomic tumor aberrations, or other targetable genomic abnormalities with approved first-line targeted therapy, such as nsclc with ros1 rearrangement, braf v600e mutation, ntrk 1/2/3 gene fusion, met ex14 skipping mutation, and ret rearrangement

  • M1413

    Patients who had a positive pd-l1 biomarker expression test result prior to the initiation of first-line immune checkpoint inhibitor therapy

  • M1414

    Documentation of medical reason(s) for not performing the pd-l1 biomarker expression test prior to initiation of first-line immune checkpoint inhibitor therapy (e.g., patient is in an urgent or emergent situation where delay of treatment would jeopardize the patient's health status; other medical reasons/contraindication)

  • M1415

    Patients who did not have a positive pd-l1 biomarker expression test result prior to the initiation of first-line immune checkpoint inhibitor therapy

  • M1416

    Patient received hospice services any time during the performance period

  • M1417

    Patients who are up to date on their covid-19 vaccinations as defined by cdc recommendations on current vaccination

  • M1418

    Patients who are not up to date on their covid-19 vaccinations as defined by cdc recommendations on current vaccination because of a medical contraindication documented by clinician

  • M1419

    Patients who are not up to date on their covid-19 vaccinations as defined by cdc recommendations on current vaccination

  • M1420

    Complete ophthalmologic care mips value pathway

  • M1421

    Dermatological care mips value pathway

  • M1422

    Gastroenterology care mips value pathway

  • M1423

    Optimal care for patients with urologic conditions mips value pathway

  • M1424

    Pulmonology care mips value pathway

  • M1425

    Surgical care mips value pathway

  • M1426

    Encounters conducted via telehealth

  • M1427

    Documentation of medical reason(s) for performing a bone scan (including documented pain related to prostate cancer, salvage therapy, other medical reasons)

  • M1428

    Patients who have bilateral absence of eyes any time during the patient's history through the end of the measurement period

  • M1429

    Retinal exam finding with evidence of retinopathy in left, right or both eyes with severity level documented
  • Continued

  • M1430

    Retinal exam finding without evidence of retinopathy in both eyes with severity level documented (in measurement year or in the prior year)

  • M1431

    Encounters conducted via telehealth

  • M1432

    Encounters conducted via telehealth

  • M1433

    Patient on oral chemotherapy on or within 30 days before denominator eligible encounter

  • M1434

    Patient on oral chemotherapy on or within 30 days after denominator eligible encounter

  • M1435

    Patient on oral chemotherapy during the performance period

  • M1436

    Encounters conducted via telehealth

  • M1437

    Encounters conducted via telehealth

  • M1438

    Time last known well to hospital arrival less than or equal to 3.5 hours (<= 210 minutes)

  • M1439

    Significant ocular conditions that impact the visual outcome of surgery

  • M1440

    Encounters conducted via telehealth

  • M1441

    Encounter corresponds to initial diagnosis of sleep apnea or first contact with sleep apnea diagnosed patient

  • M1442

    Encounters conducted via telehealth

  • M1443

    Encounters conducted via telehealth

  • M1444

    Delivery at < 39 weeks of gestation

  • M1445

    Postpartum care visit before or at 12 weeks of giving birth

  • M1446

    Patients who died any time prior to the end of the measure assessment period

  • M1447

    Patients with an active diagnosis of bipolar disorder any time prior to the end of the measure assessment period

  • M1448

    Patients with an active diagnosis of personality disorder any time prior to the end of the measure assessment period

  • M1449

    Patients with an active diagnosis of schizophrenia or psychotic disorder any time prior to the end of the measure assessment period